Tobias Arkenau

[@EllipsesPharma @ellipsespharma]

Explore the cutting-edge of lung cancer treatment with @EllipsesCMO. Learn about the latest breakthroughs in clinical trials and the growing demand for next-generation therapies. Read more: https://t.co/cBsrpx5Cj5 #LungCancer #PrecisionMedicine #Innovation #EllipsesPharma

[@EllipsesPharma @ellipsespharma]

AS SEEN ON TV: Learn about our role in advancing Precision Medicine and how we validate promising assets through our Scientific Advisory Group. Check out the interview: https://t.co/lTRAaR0lth #PrecisionMedicine #EllipsesPharma

[@EllipsesPharma @ellipsespharma]

EP0031, our next-gen RET inhibitor, receives FDA Orphan Drug Designation. A crucial step in advancing cancer treatments. #OrphanDrug #EP0031 #EllipsesPharma https://t.co/0MliPuHixm

[@EllipsesPharma @ellipsespharma]

📄 Access the poster presentation for Asset EP0031, shared by @EllipsesCMO at @AACR Boston. Dive into the details and join us in advancing cancer research!💡https://t.co/ZgVKtD6NXM
#AACR2023 #CancerInnovation 🚀

[Stephen V Liu, MD @StephenVLiu]

#Targets23 Great work from Drs. @AriMarinel @mihaela_aldea and others on characterizing outcomes in #RET NSCLC post progression on selective inhibitors: patterns of progression, response to subsequent lines of therapy.

[Stephen V Liu, MD @StephenVLiu]

I was happy to see Dr. @ElenaGarralda again - presenting work on EP0031, a next generation #RET inhibitor with impressive efficacy after selective RET inhibitors and CNS efficacy. #Targets23

[Tobias Arkenau @EllipsesCMO]

Thrilled to be a speaker at the Economist Impact World Cancer Series Europe 2023 on Sept 20th - 21st. Join me and the panel as we discuss Women's Cancer. Together, we can make a meaningful impact! #EconWorldCancerSeries #CancerResearch #WomensHealth

[RET Renegades @RetRenegades]

Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With ... - https://t.co/ZpZanzqUGu #GoogleAlerts #RETcancer #Lungcancer #researchmaters

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

🎯 🧬 KL590586 (A400/EP0031)
A next-generation selective RET inhibitor in patients with RET-altered solid tumors. ORR 60% and DCR 95% for all tumor types and doses. 🫁 In NSCLC: ORR 81% in 1L and 70% in 2L. Also 🧠 activity proven #ASCO23 #LCSM

[Tobias Arkenau @EllipsesCMO]

Next generation selective RET inhibitor EP0031/A400 - convincing and solid data presented by Prof Zhou.

[Tobias Arkenau @EllipsesCMO]

@myESMO @TeresaSAmaral @LuisCB_MedPharm @MartijnLolkema @ViktorGruenwald @ruthvera_onco @JlgraciaMD Great opportunity to get this right - we have learnt so much post COVID, new technologies widely available to streamline and reduce burden of bureaucracy in clinical development - Onwards ESMO/ECRO task force!

[ESMO - Eur. Oncology @myESMO]

The burden of bureaucracy in clinical research has increased for investigators & clinical research teams. ESMO proposes a framework to streamline clinical research & reduce the bureaucracy in clinical trials, promoting better care for cancer patients.
🔗https://t.co/QzKyv0kHv1

[Tobias Arkenau @EllipsesCMO]

Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors https://t.co/xt0ExryFhB

[Sarah Cannon Docs @SarahCannonDocs]

We are excited to share our latest cancer research insights through more than 140 abstracts and presentations at #ASCO22. Read about where you can find our scientific experts at this year’s annual meeting. https://t.co/IpYCTDGxUQ

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Excited to be on our first call for the new ⁦@ASCO⁩ monthly plenary series.

See attached for dates of presentations and submissions. Exciting to get data out there within 5-6 weeks of submission.

Monthly Plenary Series | ASCO https://t.co/uOinLy8T9x

[VJHemOnc @VJHemOnc]

Be the first to hear the latest HemOnc news and best practice from the world’s leading experts 👨‍🔬👩‍🔬 Stay tuned for videos, podcasts and articles published live from the latest virtual meetings!

#HemOnc #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #BleedingDisorders

[Tobias Arkenau @EllipsesCMO]

@SarahCannonDocs @deehubie Congratulations Dee Anna from across the pond - great leadership has made Sarah Cannon a great success - hopefully more to come!

[Sarah Cannon Docs @SarahCannonDocs]

Happy Fourth of July! Wishing you a safe and enjoyable holiday with friends and family. #July4th

[VJ Oncology @VJOncology]

🕙 Just 10 days to go until ESMO #WorldGI2021 starts and @VJOncology are excited to report on the biggest news from the meeting

Check out 👉 https://t.co/qH0bG8agF6 👈 for exclusive interviews, podcasts and more!

@myESMO #CRCSM #HPBCsm #STCsm #ESOCsm #GICancer #ayacsm

[Tobias Arkenau @EllipsesCMO]

@VJOncology @dmukherji @LizzySmyth1 Good fun today - great discussions!